| Journal | Journal of cardiothoracic surgery |
| Study Type | Clinical Study |
| Population | Human participants |
This large-scale retrospective analysis provides reassuring evidence that cannabis use disorder does not independently increase surgical risk in cardiac patients. It challenges potential surgical gatekeeping based solely on cannabis use while highlighting the clinical reality of polysubstance patterns.
This retrospective cohort study analyzed 846,837 cardiovascular surgery patients from the Nationwide Readmissions Database (2016-2018), identifying 11,724 (1.4%) with cannabis use disorder. Using 1:1 propensity score matching to control for baseline characteristics, researchers found no association between CUD and increased in-hospital morbidity or mortality following cardiac surgery. However, patients with CUD demonstrated significantly higher rates of concomitant substance use including tobacco, opioids, cocaine, and alcohol. The study’s observational design and reliance on diagnostic coding limit causal inference, but the large sample size strengthens external validity.
“I find this data clinically liberating—it supports what many of us have observed that cannabis use alone shouldn’t disqualify patients from necessary cardiac interventions. The polysubstance clustering is the real clinical concern that demands our attention and coordinated care.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Should cannabis use disorder be considered a contraindication to cardiovascular surgery?
No, this study found that cannabis use disorder was not associated with additional in-hospital morbidity or mortality following cardiovascular surgery. Cannabis use disorder alone should not preclude patients from undergoing necessary cardiovascular procedures.
What is the prevalence of cannabis use disorder among cardiovascular surgery patients?
Based on this nationwide database analysis, approximately 1.4% of patients undergoing cardiovascular surgery between 2016-2018 had cannabis use disorder. This represents 11,724 patients out of 846,837 total cardiovascular surgery cases during the study period.
Are patients with cannabis use disorder at higher risk for other substance abuse issues?
Yes, the study found that cannabis use disorder serves as a marker for polysubstance abuse. Patients with cannabis use disorder had significantly higher rates of concomitant smoking/nicotine use, opioid abuse, cocaine/stimulant abuse, and alcohol abuse compared to matched controls.
What special considerations should be made for cardiovascular surgery patients with cannabis use disorder?
While cannabis use disorder itself doesn’t increase surgical risks, clinicians should screen for and manage concomitant substance abuse disorders. These patients represent a vulnerable population requiring comprehensive substance abuse treatment alongside their cardiac care.
How should perioperative teams approach cannabis-using patients scheduled for cardiac surgery?
Teams should focus on comprehensive substance abuse assessment rather than cannabis use alone. The priority should be identifying and managing polysubstance use patterns, as the cannabis use disorder may indicate broader addiction issues that require coordinated treatment during the perioperative period.
